NEW YORK (GenomeWeb News) - TriLink Biotechnologies, a maker of customized nucleic acid products, said today it has received a $100,000 Phase I Small Business Innovation Research grant from the National Institutes of Health to study a novel approach to PCR activation.
 
The NIH's National Institute of General Medical Sciences awarded the grant.
 
The company said its so-called Hot Start PCR method uses chemically modified triphosphates that inhibit DNA polymerase activity until a thermal activation step.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.